Logo

People in the News: Peter Heseltine, Mark Emberton

May 30, 2014
Premium

Singulex has appointed Peter Heseltine as chief medical officer.

Heseltine is professor of Clinical Medicine at the University of California, Irvine. Previously he was senior vice president and chief medical officer at Prometheus Laboratories. He also held executive positions at Beckman Coulter and Quest Diagnostics.

ProteoMedix has named Mark Emberton as a clinical advisor.

Emberton is director of the Division of Surgery and Interventional Science at University College, London as well as a founding partner of London Urology Associates.

Filed under

Proteomics & Protein Research
proteomics
Singulex
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.